Clinigen logo

CLIN - Clinigen News Story

855.5p -0.5  -0.1%

Last Trade - 18/05/21

Sector
Healthcare
Size
Mid Cap
Market Cap £1.14bn
Enterprise Value £1.49bn
Revenue £518.7m
Position in Universe 404th / 1824

Clinigen Group plc - Clinigen to begin supplying Erwinase® in the UK

Tue 6th April, 2021 7:00am
RNS Number : 4604U
Clinigen Group plc
06 April 2021
 

6 April 2021

 

 

Clinigen to begin supplying Erwinase® in the UK

 

Clinigen Group plc (AIM: CLIN, 'Clinigen'), the global pharmaceutical Products and Services company, today announces that it will be providing access to Erwinase® (L-asparaginase Erwinia chrysanthemi) in the UK from the 6 April 2021. This is part of the global exclusive licensing and distribution agreement with Porton Biopharma ('PBL'), as previously announced on 16 April 2020.

 

Erwinase is approved in the UK as a component of a chemotherapeutic regimen for the treatment of patients with acute lymphoblastic leukaemia (ALL) who have developed hypersensitivity to E. coli-derived asparaginase.  Erwinase is manufactured by PBL (PL 44403/0002) and Clinigen is responsible for marketing, packaging, labelling, storage and distribution.

 

With the onboarding of Erwinase coming earlier than originally anticipated this will bring forward an expected investment in working capital in-line with our previous guidance of £10m - £20m. Given the proximity to the year end and staggered roll out across each territory this is not expected to have a material impact on current year profit expectations.

 

Sam Herbert, Chief Operating Officer, Clinigen, said:

 

"Erwinase® is an important treatment option for healthcare professionals in the UK and this represents a major milestone since partnering with PBL. PBL has invested in enhancing its manufacturing to increase Erwinase® capacity and our ongoing focus is to ensure effective future supply in the UK and in other international markets where patients need access. At Clinigen our mission is to ensure the right medicines get to the right patients at the right time and we see Erwinase® as a key part of that mission."

 

Healthcare professionals can obtain ordering details about Erwinase by calling the Clinigen customer service team at +44 (0) 1932 824100 or emailing MedicineAccess@clinigengroup.com.

 

Patients seeking medical information should contact their physician.

 

- Ends -

 

Contact details

Clinigen Group plc

Tel: +44 (0) 1283 495010

Sam Herbert, Chief Operating Officer

Investors@Clinigen.com

 

 

Numis Securities Limited - Nominated Adviser & Joint Broker

Tel: +44 (0) 20 7260 1000

James Black / Garry Levin / Freddie Barnfield

Clinigen@Numis.com

 

 

RBC Capital Markets - Joint Broker

Tel: +44 (0) 20 7653 4000

Marcus Jackson / Elliot Thomas

 

 

 

Instinctif Partners

Tel: +44 (0) 20 7457 2020

Melanie Toyne-Sewell / Tim Linacre / Rozi Morris / Phillip Marriage

clinigen@instinctif.com

 

 

Notes to Editors

 

About Clinigen Group

Clinigen Group plc (AIM: CLIN) is a global, specialist pharmaceutical services and products platform focused on providing ethical access to medicines. Its mission is to deliver the right medicine to the right patient at the right time. The Group operates from sites in North America, Europe, Africa and the Asia Pacific.

Clinigen has more than 1,250 employees across five continents in 16 countries, with supply and distribution hubs and operational centres of excellence in key long-term growth regions. The Group works with 34 of the top 50 pharmaceutical companies; interacting with over 5,000 hospitals across more than 115 countries.

For more information on Clinigen, please visit http://www.clinigen.com 

 

About Erwinase® / Erwinaze® 

Erwinase is indicated as a component of a chemotherapeutic regimen for the treatment of patients with acute lymphoblastic leukaemia (ALL) who have developed hypersensitivity to E. coli-derived asparaginase. Erwinase is indicated in paediatric patients from the age of 4 months and in adults.

Asparagine is an amino acid that is essential for cell growth; it is produced by most but not all cells. Mutated cancer cells in ALL rely on asparagine circulating in the blood for growth. L-asparaginases are a group of enzymes that lower circulating asparagine levels in the blood, thereby depriving the mutated cells of asparagine and inhibiting their growth.

There are several different types of L-asparaginase available on the market, each derived from a different bacterium. Patients receiving treatment with L-asparaginase derived from Escherichia coli (E. coli), who develop hypersensitivity to that form of the enzyme, may be able to continue treatment with Erwinase as the enzymes are immunologically distinct. Antibodies targeting E. coli derived L-Asparaginase have been shown not to cross-react with Erwinase.

About Acute Lymphoblastic Leukaemia (ALL)

Acute lymphoblastic leukemia (ALL) is a heterogenous hematologic disease characterized by the proliferation of immature lymphoid cells in the bone marrow, peripheral blood and other organs. Both adults and children can get the illness, but it is most often diagnosed in younger people. The incidence in the EU is thought to be 1.28 per 1 000 000 individuals annually, with significant age-related variations. Estimated new ALL cases in the US was estimated to be 6150 in 2020 according to the SEER program.


About Porton Biopharma Limited (PBL)

PBL is a biopharmaceutical development and manufacturing company. It was formed in April 2015 as a spin-out company of Public Health England, part of the Department of Health and Social Care.  PBL is based at Porton Down, Wiltshire, which has a long history of pharmaceutical development and manufacturing. Erwinase, the UK's anthrax vaccine, Dysport and other medical treatments have been developed at the site by the forerunners to PBL. PBL has approximately 350 staff and has a sole shareholder in the Department of Health and Social Care.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCDBGDSSXGDGBU
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.